Bolt Biotherapeutics Reports Exit/Disposal Activities
Ticker: BOLT · Form: 8-K · Filed: Oct 2, 2025 · CIK: 1641281
| Field | Detail |
|---|---|
| Company | Bolt Biotherapeutics, Inc. (BOLT) |
| Form Type | 8-K |
| Filed Date | Oct 2, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.00001, $1.5 million, $2.0 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: restructuring, disposal, corporate-action
TL;DR
Bolt Bio is exiting/disposing of something, details TBD.
AI Summary
Bolt Biotherapeutics, Inc. filed an 8-K on October 2, 2025, reporting on cost associated with exit or disposal activities and other events as of October 1, 2025. The filing does not contain specific financial figures or details regarding the nature of these exit or disposal activities.
Why It Matters
This filing indicates potential restructuring or winding down of certain operations by Bolt Biotherapeutics, which could impact its future business strategy and financial performance.
Risk Assessment
Risk Level: medium — The filing suggests significant business changes, but lacks specific details, creating uncertainty about the company's future direction and financial health.
Key Players & Entities
- Bolt Biotherapeutics, Inc. (company) — Registrant
- October 1, 2025 (date) — Earliest event reported
- October 2, 2025 (date) — Filing date
- Delaware (jurisdiction) — State of Incorporation
- 900 Chesapeake Drive, Redwood City, California 94063 (address) — Principal Executive Offices
FAQ
What specific activities are associated with the 'exit or disposal' mentioned in the filing?
The filing does not specify the nature of the cost associated with exit or disposal activities.
What are the 'other events' reported by Bolt Biotherapeutics?
The filing does not provide details on the specific 'other events' that were reported.
When was the earliest event reported in this 8-K filing?
The earliest event reported was as of October 1, 2025.
What is the principal executive office address for Bolt Biotherapeutics, Inc.?
The principal executive offices are located at 900 Chesapeake Drive, Redwood City, California 94063.
What is the SEC file number for Bolt Biotherapeutics, Inc.?
The SEC file number for Bolt Biotherapeutics, Inc. is 001-39988.
Filing Stats: 711 words · 3 min read · ~2 pages · Grade level 11.7 · Accepted 2025-10-02 16:05:26
Key Financial Figures
- $0.00001 — ch registered Common Stock, par value $0.00001 per share BOLT The Nasdaq Capital M
- $1.5 million — e pre-tax charges between approximately $1.5 million to $2.0 million in connection with the
- $2.0 million — s between approximately $1.5 million to $2.0 million in connection with the reduction-in-for
Filing Documents
- bolt-20251001.htm (8-K) — 51KB
- bolt-ex99_1.htm (EX-99.1) — 17KB
- img192637872_0.jpg (GRAPHIC) — 12KB
- 0001193125-25-228293.txt ( ) — 201KB
- bolt-20251001.xsd (EX-101.SCH) — 28KB
- bolt-20251001_htm.xml (XML) — 5KB
05 Costs Associated with Exit or Disposal Activities
Item 2.05 Costs Associated with Exit or Disposal Activities. On October 1, 2025, Bolt Biotherapeutics, Inc., a Delaware corporation (the "Company"), implemented a restructuring plan pursuant to which it will reduce overall operating expenses to preserve cash. The restructuring plan includes a reduction of the Company's current workforce by approximately 20 employees, or approximately 50% of the Company's workforce. The Company estimates that it will incur aggregate pre-tax charges between approximately $1.5 million to $2.0 million in connection with the reduction-in-force, primarily consisting of severance payments, employee benefits, and related costs. The Company expects that the reduction-in-force will be complete by the end of 2025 and that the associated charges will be recorded in the fourth quarter of 2025. The estimated charges that the Company expects to incur are subject to a number of assumptions, and actual results may differ materially from these estimates. The Company may also incur additional costs not currently contemplated due to events that may occur as a result of, or that are associated with, the restructuring plan.
01 Other Events
Item 8.01 Other Events On October 1, 2025, the Company announced an update on the ongoing Phase 1 dose escalation study of BDC-4182, a next-generation Boltbody ISAC clinical candidate targeting claudin 18.2, a clinically validated target in oncology. A strong immune response was observed at the initial dose levels and the Company is in the process of modifying the clinical trial protocol to allow for step-up dosing, which has been successfully used commercially for T-cell engagers. BDC-4182 preclinical data supports this approach. As a result of the update to the clinical trial protocol for BDC-4182, the Company now expects to report initial clinical data in the third quarter of 2026. To conserve capital and maintain long-term shareholder value, the Company is implementing a workforce reduction as described in Item 2.05, extending its cash runway into 2027. A press release announcing the reduction-in-force described in Item 2.05 and the update on the ongoing Phase 1 dose escalation study of BDC-4182 is filed hereto as Exhibit 99.1. Exhibit No. Description 99.1 Press Release dated October 1, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Bolt Biotherapeutics, Inc. Date: October 2, 2025 By: /s/ William P. Quinn William P. Quinn President, Chief Executive Officer and Chief Financial Officer